Search results
Showing 31 to 45 of 146 results for pneumonia
This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM106
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Digital technologies to support self-management of asthma: early value assessment
In development Reference number: GID-HTE10063 Expected publication date: 17 April 2026
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
We've mapped relevant NICE guidance and advice to NHS England’s Core20PLUS5 for adults
Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)
Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.
View recommendations for HTG244Show all sections
Sections for HTG244
Gastro-oesophageal reflux in children and young people (QS112)
This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.
View quality statements for QS112Show all sections
Sections for QS112
- Quality statements
- Quality statement 1: Information about gastro-oesophageal reflux (GOR) in infants
- Quality statement 2: Breast-fed infants – feeding assessment
- Quality statement 3: Formula-fed infants – stepped-care approach
- Quality statement 4: Alginate therapy
- Quality statement 5: Symptoms that do not need investigation or treatment
- Quality statement 6: Acid-suppressing drugs
- Quality statement 7: Upper gastrointestinal (GI) contrast study
Pharyngeal electrical stimulation for neurogenic dysphagia (HTG709)
Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.
View recommendations for HTG709Show all sections
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
A clear focus on Chronic Obstructive Pulmonary Disease (COPD) driving up uptake of Covid, Flu and Pneumonia vaccines to reduce infective exacerbations and emergency hospital admissions due to those exacerbations.
Insertion of metal rib reinforcements to stabilise a flail chest wall (HTG234)
Evidence-based recommendations on insertion of metal rib reinforcements to stabilise a flail chest wall. This involves using metal (usually titanium) to stabilise the ‘flail’ segment of chest wall.
View recommendations for HTG234Show all sections
Sections for HTG234